If CD62L+CD4+ T cells from sensitized WT spleen could develop asthma in naïve ELP-/-, it also indicates that development of asthma may not be entirely dependent on ELP-/- B cells in the spleens of these ELP-/- recipients or that the 5 million CD62L+ sensitized CD4+T cells are sufficiently potent to go into circulation and generate at least threshold amount of IgE for required airway inflammatory response. The gene discussed is SELL; the disease is asthma.